Jeremy Soule, MD
Endocrinology, Diabetes & Metabolism · Bridgeport, WVNPI 1467560326
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,399 of the $108,636 with a category attached, or 83.2%. Novo Nordisk accounts for 61.0% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $83,982 and has fallen 99.7% since, to $210 in 2024. Among endocrinology, diabetes & metabolism clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 397 payments — averaging $273.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$66K
- AstraZeneca$19K
- Lilly USA, LLC$8K
- Boehringer Ingelheim$8K
- Amgen$2K
- Johnson & Johnson$882
- plus $4K from 20 others
Across 2 payments — averaging $5800.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$12K
What the payments were for
- Consulting fees$2,9253%
- Speaking & faculty fees$90,39983%
- Travel & lodging$6,9416%
- Food & beverage$8,1427%
- Education$2300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 112 | $66,268 |
| AstraZeneca(2 entities) | 46 | $19,421 |
| Lilly USA, LLC | 35 | $8,284 |
| Boehringer Ingelheim | 31 | $8,171 |
| Amgen(2 entities) | 35 | $1,770 |
| Johnson & Johnson | 8 | $882 |
| Dexcom, Inc. | 16 | $868 |
| Insulet Corporation | 21 | $806 |
| Sanofi-aventis U.S. LLC | 22 | $624 |
| Abbott | 30 | $546 |
| Medtronic(2 entities) | 7 | $239 |
| Tandem Diabetes Care, Inc. | 5 | $185 |
| Nevro Corp. | 2 | $145 |
| AbbVie | 5 | $97 |
| Merck | 5 | $78 |
| Amarin Pharma, Inc. | 4 | $61 |
| Corcept Therapeutics | 3 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $25 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Philips North America LLC | 1 | $11 |
| Janssen Scientific Affairs, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$39,839
- FARXIGA$18,972
- JARDIANCE$15,307
- RYBELSUS$13,283
- Tresiba$10,153
- TEPEZZA$1,050
- INVOKANA$820
- Omnipod$268
- DEXCOM G7 GSS (161)$161
- Senza$133
- MOUNJARO$120
- FREESTYLE LIBRE 3$115
- MINIMED 780G$112
- Repatha$100
- DEXCOM G6 TRANSMITTER$100
How this compares
$108,636 in reported general payments places this provider in the 95th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
See all endocrinology, diabetes & metabolism providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $47,341 |
| MounjaroTirzepatide | 15 | $29,069 |
| TrulicityDulaglutide | 15 | $28,719 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $19,185 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $18,734 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $14,184 |
| VascepaIcosapent Ethyl | 13 | $6,569 |
| NovologInsulin Aspart | 17 | $6,124 |
| SynthroidLevothyroxine Sodium | 48 | $3,887 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $3,796 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,744 |
| Levothyroxine Sodium | 91 | $1,004 |
| Metformin Hcl ErMetformin Hcl | 33 | $338 |
| Rosuvastatin Calcium | 21 | $243 |
| Methimazole | 34 | $190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $8,284 | $57,78830 claims |
| Novo NordiskOzempic, Novolog | $66,268 | $53,46449 claims |
| AbbVieSynthroid | $97 | $3,88748 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $1,00491 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 endocrinology, diabetes & metabolism providers in West Virginia.
Other endocrinology, diabetes & metabolism in Bridgeport
- John EplingBridgeport$28K
- Timothy JacksonBridgeport$7K
- Daniel MaciasHuntington$686K
- Zachary KistkaMartinsburg$120K
- Philip RyanMartinsburg$35K
- Greta GuyerSouth Charleston$22K
- Arlene FederWeirton$20K
- Ziad KahwashSouth Charleston$17K
- Ayman ElkadryHuntington$13K
- Jessica PeriniMorgantown$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.